KRN-101 for Cancer-Related Distress

This study will investigate the effects of KRN-101 (a psilocybin-based medicine) in participants with cancer-related distress.

Topic Anxiety Depression
Compound Psilocybin
Country United Kingdom
Visit trial
Status Planned
Results Published
Phase Phase II
Design Open
Type Interventional
Generation Second
Sex All
Therapy No

Trial Details



Trial Number

Sponsors & Collaborators

Albert Labs
Albert Labs is a publicly listed company (CSE) that uses Real-World Evidence (RWE) to accelerate the psychedelic drug development process.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.